The pioneering biotechnology project CarbaZymes, funded with € 8,2 million by the EU’s Horizon 2020 Research and Innovation Programme, held its mid-term review meeting in Brussels in the Mondrian building (CDMA), which houses the Directorate General for Research & Innovation, on 9th September 2016.
Led by the coordinator, Professor W.-D. Fessner from the Technische Universität Darmstadt, PIs, researchers and managers of 7 universities, 6 SMEs and 1 large company met with the Project Officer Dr A. Fuentes and external reviewer Assoc. Professor E. Atanes. The consortium presented its cutting-edge advances of the project so far, which lie in the area of asymmetric C-C bond formation to obtain high value APIs and essential bulk compounds for industry, starting from potentially sustainable, low priced precursors, by applying novel, engineered biocatalysts.
The CarbaZymes Project, with a collective scientific experience of more than 150 years(!) in biocatalysis, aims to revolutionize certain production methods in the chemical industry and then scale them up to demonstration level. After securing IP, these will be ready to be taken up by the relevant industries. The processes of interest to the CarbaZymes platform aspire to be more efficient and more eco-friendly versions of some widely applied conventional organic chemical syntheses, with the aim to replace potential hazards for the benefit of human health and positively impact the future quality of life for European citizens.
The review meeting was highly successful and the CarbaZymes consortium was encouraged to further pursue novel and emerging spin-off developments along with the main goals of the project.
Note to interested parties:
For more information or interviews, please contact the project manager: